Department of Surgery/Division of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.
Otolaryngol Head Neck Surg. 2012 Apr;146(4):664-8. doi: 10.1177/0194599811432423. Epub 2012 Jan 6.
The Draf III procedure is an advanced surgical option for frontal sinus disease refractory to endoscopic frontal sinusotomy and is used to expose the anterior limit of resection of the skull base during endoscopic management of anterior skull base tumors. Our objective was to evaluate outcomes of a strategy using mucosal grafts to decrease postoperative closure.
Prospective cohort.
Tertiary care facility.
Patients requiring a Draf III procedure were prospectively enrolled in the study. Demographics, reason for the procedure, percentage graft viability, and complications were recorded. The primary outcome measure was anterior-posterior (AP) diameter at 3 months.
Mucosal grafting was performed during 29 Draf III procedures from 2008 to 2011. Twenty-seven patients (average age, 58 years) were available for measurement at 3 months (average postoperative follow-up, 15.4 months; range, 3-30 months). Reasons for the procedure included tumor (n = 14), chronic rhinosinusitis (CRS) with frontal ostium stenosis (n = 12), and trauma (n = 1). Average intraoperative AP diameter was 11.7 mm. All patients met the definition of success (<50% reduction in diameter), maintaining a patent combined frontal sinus ostium for the duration of follow-up (average diameter 10.8 mm at 3 months). Nine patients with CRS and frontal ostium stenosis had openings similar to the entire cohort (>1-year follow-up; average, 19.3 months) with significant symptom reduction (SNOT-22 preop 62.3 ± 20.8 vs 3 months 27.8 ± 14.8 and 1 year 21.4 ± 13.6; P < .0001).
Cicatricial stenosis and osteoneogenesis are common following the Draf III procedure. This study indicates that the use of mucosal grafts may assist with postoperative stenosis and should be considered a routine strategy for preventing closure.
Draf III 手术是一种针对经内镜额窦切开术治疗无效的额窦疾病的高级手术选择,用于在经内镜前颅底肿瘤治疗中暴露颅底切除的前极限。我们的目的是评估使用黏膜移植物减少术后闭合的策略的结果。
前瞻性队列研究。
三级保健机构。
前瞻性招募需要 Draf III 手术的患者参与该研究。记录人口统计学资料、手术原因、移植物存活率百分比和并发症。主要结局测量指标为术后 3 个月时的前后(AP)直径。
2008 年至 2011 年间,共进行了 29 例 Draf III 手术,其中 27 例患者(平均年龄 58 岁)可在术后 3 个月进行测量(平均术后随访 15.4 个月;范围 3-30 个月)。手术原因包括肿瘤(n = 14)、慢性鼻-鼻窦炎伴额窦口狭窄(n = 12)和外伤(n = 1)。平均术中 AP 直径为 11.7 毫米。所有患者均符合成功标准(直径缩小<50%),在整个随访期间保持了通畅的联合额窦口(术后 3 个月平均直径为 10.8 毫米)。9 例 CRS 伴额窦口狭窄的患者与整个队列相似(>1 年随访;平均 19.3 个月),症状显著缓解(SNOT-22 术前 62.3 ± 20.8 与术后 3 个月 27.8 ± 14.8 和 1 年 21.4 ± 13.6;P<.0001)。
Draf III 手术后常见瘢痕性狭窄和骨生成。本研究表明,使用黏膜移植物可能有助于术后狭窄,应被视为预防闭合的常规策略。